Rickettsia Clearance Study
Launched by LAO-OXFORD-MAHOSOT HOSPITAL WELLCOME TRUST RESEARCH UNIT · Jul 31, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Rickettsia Clearance Study is a clinical trial aimed at understanding how well certain antibiotics work for treating infections caused by rickettsial bacteria, specifically murine typhus and scrub typhus. These diseases can be serious and are often hard to diagnose. The study is looking for adult participants who test positive for either murine typhus or scrub typhus, can take oral medications, and are willing to stay in the hospital for at least 36 hours. It's important that participants are not pregnant or breastfeeding, and they shouldn't have had recent treatments with certain antibiotics before joining the trial.
If you participate in this study, you will receive treatment and be closely monitored by healthcare professionals. The goal is to learn more about the effectiveness of different antibiotics and to find better ways to manage these infections. This research could help improve treatment options for many people suffering from these diseases in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age above or equal 18 years
- • Able to take oral medication
- • Rapid test positive for murine typhus or scrub typhus
- • Agrees to stay in hospital for at least 36 hours and to attend for scheduled follow up visits
- • Written informed consent to participate in the study
- • A negative urinary pregnancy test for all women of child-bearing age
- Exclusion Criteria:
- • Pregnancy or breast feeding
- • Previous allergic reaction to doxycycline or azithromycin
- • Received more than one dose of chloramphenicol, doxycycline, tetracycline, fluoroquinolones, rifampicin or azithromycin during this hospital admission or more than one dose of any of these drugs in the week before admission
- • Contraindication to doxycycline: severe hepatic impairment, known SLE
- • Contraindication to azithromycin: sever hepatic impairment
- * Severe typhus defined as the presence of one or more of the following:
- • 1. Reduced level of consciousness
- • 2. Clinical jaundice
- • 3. Shock (BP systolic \<80 mmHg)
- • 4. Unable to take oral medication
- • 5. Radiological evidence of pneumonia
- • 6. Clinical evidence for meningitis/encephalitis or the need of LP
- • 7. Alternative diagnosis confirmed that explains the presenting symptoms
- • 8. Any other syndrome which in the opinion of the admitting doctor constitutes severe typhus (reason must be stated)
About Lao Oxford Mahosot Hospital Wellcome Trust Research Unit
The Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit is a leading clinical research institution based in Vientiane, Laos, dedicated to advancing global health through high-quality research. It operates at the intersection of clinical medicine and epidemiology, focusing on infectious diseases, tropical medicine, and public health challenges in Southeast Asia. Supported by the Wellcome Trust, the unit collaborates with international and local partners to conduct innovative clinical trials, promote capacity building, and enhance healthcare delivery. Its commitment to ethical research practices and community engagement ensures that findings contribute to improving health outcomes in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vientiane, Vientaine, Lao People's Democratic Republic
Vientiane Province, , Lao People's Democratic Republic
Patients applied
Trial Officials
Weerawat Phuklia, PhD
Principal Investigator
Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported